Literature DB >> 30250519

Echinocandins for Pneumocystis jirovecii pneumonia in non-HIV patients: A case report.

Hui-Bin Huang1,2, Jing-Min Peng1, Bin Du1.   

Abstract

For the past two decades, echinocandins have shown prophylactic and therapeutic efficacy in patients with Pneumocystis jirovecii pneumonia (PJP), due to their ability to inhibit the synthesis of β-1, 3-glucan, a major component of the cell wall of P. jirovecii. The present study reported two cases of human immunodeficiency virus (HIV)-negative patients who received echinocandins as a salvage therapy at Peking Union Medical College Hospital (Beijing, China), both of whom exhibited good responses to treatment. In both cases, polymerase chain reaction of sputum or bronchoalveolar lavage specimens became negative following treatment. The present study also performed a literature search to identify non-HIV patients with PJP who previously received echinocandins. The results of the present study suggested that echinocandins maybe promising therapeutic agents in the treatment of non-HIV patients with PJP, particularly in combination with trimethoprim-sulfamethoxazole. Therefore, the results warrant a randomized controlled trial.

Entities:  

Keywords:  Pneumocystis jirovecii pneumonia; echinocandins; non-human immunodeficiency viruspatients

Year:  2018        PMID: 30250519      PMCID: PMC6143981          DOI: 10.3892/etm.2018.6587

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  27 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  A trial of caspofungin salvage treatment in PCP pneumonia.

Authors:  Darius Armstrong-James; Justin Stebbing; Laurence John; Andrew Murungi; Mark Bower; Brian Gazzard; Mark Nelson
Journal:  Thorax       Date:  2010-09-29       Impact factor: 9.139

3.  Caspofungin treatment of Pneumocystis pneumonia during conditioning for bone marrow transplantation.

Authors:  C Annaloro; A Della Volpe; P Usardi; G Lambertenghi Deliliers
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-01       Impact factor: 3.267

4.  Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors.

Authors:  D M Schmatz; M A Romancheck; L A Pittarelli; R E Schwartz; R A Fromtling; K H Nollstadt; F L Vanmiddlesworth; K E Wilson; M J Turner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

5.  Combined trimethoprim and caspofungin treatment for severe Pneumocystis jiroveci pneumonia in a five year old boy with acute lymphoblastic leukemia.

Authors:  K Beltz; C M Kramm; H-J Laws; H Schroten; R Wessalowski; U Göbel
Journal:  Klin Padiatr       Date:  2006 May-Jun       Impact factor: 1.349

6.  Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIV-infected individuals.

Authors:  Ming-Chi Li; Nan-Yao Lee; Ching-Chi Lee; Hsin-Chun Lee; Chia-Ming Chang; Wen-Chien Ko
Journal:  J Microbiol Immunol Infect       Date:  2012-10-11       Impact factor: 4.399

Review 7.  Combination of caspofungin and low-dose trimethoprim/sulfamethoxazole for the treatment of severe Pneumocystis jirovecii pneumonia in renal transplant recipients.

Authors:  Guo-Wei Tu; Min-Jie Ju; Ming Xu; Rui-Ming Rong; Yi-Zhou He; Zhang-Gang Xue; Tong-Yu Zhu; Zhe Luo
Journal:  Nephrology (Carlton)       Date:  2013-11       Impact factor: 2.506

8.  Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii.

Authors:  M A Powles; P Liberator; J Anderson; Y Karkhanis; J F Dropinski; F A Bouffard; J M Balkovec; H Fujioka; M Aikawa; D McFadden; D Schmatz
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

9.  A survival case of ABO-incompatible liver transplantation complicated with severe preoperative infection and subsequent overwhelming postsplenectomy infection.

Authors:  K Takeda; D Morioka; T Kumamoto; K Matsuo; K Tanaka; I Endo; S Togo; H Shimada
Journal:  Transplant Proc       Date:  2009-11       Impact factor: 1.066

Review 10.  Successful treatment of severe Pneumocystis pneumonia in an immunosuppressed patient using caspofungin combined with clindamycin: a case report and literature review.

Authors:  Hongjuan Li; Haoming Huang; Hangyong He
Journal:  BMC Pulm Med       Date:  2016-11-11       Impact factor: 3.317

View more
  2 in total

1.  Apheresis Technique for Acute Hyperlipidemic Pancreatitis: A Systemic Review and Meta-Analysis.

Authors:  You-Fei Lin; Yan Yao; Yuan Xu; Hui-Bin Huang
Journal:  Dig Dis Sci       Date:  2022-06-22       Impact factor: 3.199

2.  Non-HIV-infected patients with Pneumocystis pneumonia in the intensive care unit: A bicentric, retrospective study focused on predictive factors of in-hospital mortality.

Authors:  Yuqiong Wang; Xu Huang; Ting Sun; Guohui Fan; Qingyuan Zhan; Li Weng
Journal:  Clin Respir J       Date:  2022-01-10       Impact factor: 1.761

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.